Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocular Therapeutix's Stock Gets A Shock As Another PhIII Misses Target

Executive Summary

Ocular Therapeutix Inc.'s stock plummeted 42% on June 6 after a second Phase III study of its allergic conjunctivitis therapy, Dextenza (sustained-release dexamethasone), failed to reach its single primary endpoint – another big hit for the drug following a Phase III failure in ocular inflammation in 2015.

You may also be interested in...



Ocular Therapeutix Gets Lead Product Back On Track

The long-acting eye insert Dextenza has been accepted for review by the US FDA, a piece of good news for Ocular Therapeutix that had previously received a complete response letter on manufacturing issues and a mixed bag of late-stage clinical trial results.

Regeneron Partnering With Ocular May Provide Needed Tech Validation

Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.

Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

The latest drug development news and highlights from our FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

LL1132247

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel